Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Dan Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7066-9058; OpenAlex author ID A5021498685, A5071022452. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
62
Papers, trials and grants by year

2023: 3 papers · 2024: 3 papers · 2025: 3 papers · 2026: 4 papers

Papers 13

  1. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag071↗
  2. Clinicopathologic Characteristics of Brain Metastasis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pas.0000000000002470↗
  3. Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications. Co-author DOI 10.1158/1078-0432.ccr-26-0344↗
  4. Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po-25-00703↗
  5. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Last author DOI 10.1093/oncolo/oyae182↗
  6. KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-2024↗
  7. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13045-025-01696-0↗
  8. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41698-024-00505-0↗
  9. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II T… Co-author DOI 10.1200/jco.24.00081↗
  10. The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.3390/cancers16193312↗
  11. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.1097/pas.0000000000002013↗
  12. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Co-author DOI 10.3390/cancers15092608↗
  13. Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neo… Co-author DOI 10.3390/cancers15123231↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 10 shared papers, 2023–2026 · strength 1.82
  2. Robert A. Wolff · 10 shared papers, 2023–2026 · strength 1.80
  3. Anirban Maitra · 9 shared papers, 2023–2026 · strength 1.66
  4. Huamin Wang · 7 shared papers, 2023–2026 · strength 1.28
  5. Ching-Wei David Tzeng · 7 shared papers, 2023–2026 · strength 1.24
  6. Laura R. Prakash · 6 shared papers, 2023–2026 · strength 1.16
  7. Shubham Pant · 6 shared papers, 2024–2026 · strength 1.15
  8. Eugene Jon Koay · 7 shared papers, 2023–2025 · strength 1.14
  9. Naruhiko Ikoma · 6 shared papers, 2023–2026 · strength 1.05
  10. Michael P. Kim · 6 shared papers, 2023–2026 · strength 1.05
  11. Mahmoud Yousef · 5 shared papers, 2024–2026 · strength 1.05
  12. Hua Wang · 5 shared papers, 2023–2026 · strength 0.91
  13. Brandon George Smaglo · 5 shared papers, 2024–2026 · strength 0.89
  14. Rebecca Anne Snyder · 4 shared papers, 2024–2026 · strength 0.77
  15. Michael James Overman · 4 shared papers, 2024–2026 · strength 0.75
  16. Jason A. Willis · 4 shared papers, 2024–2026 · strength 0.70
  17. Abdelrahman M.G. Yousef · 4 shared papers, 2024–2025 · strength 0.69
  18. Deyali Chatterjee · 4 shared papers, 2023–2024 · strength 0.63
  19. Jeffrey E. Lee · 3 shared papers, 2023–2026 · strength 0.55
  20. Ryan W. Huey · 3 shared papers, 2024–2026 · strength 0.54
  21. Ethan Bernard Ludmir · 3 shared papers, 2024–2025 · strength 0.51
  22. Haoqiang Ying · 2 shared papers, 2025 · strength 0.34
  23. Yi Tat Tong · 2 shared papers, 2023–2024 · strength 0.33
  24. Mehran Taherian · 2 shared papers, 2023–2024 · strength 0.32
  25. Saikat Chowdhury · 2 shared papers, 2024–2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.